Please try another search
On Wednesday, RBC Capital initiated coverage on BioMerieux, a global player in the field of in vitro diagnostics, with an Outperform rating and a price target set at EUR 130.00. The firm's analysis...
On Thursday, HSBC (LON:HSBA) demonstrated confidence in BioMerieux (BIM:FP) (OTC: BMXMF) by raising the price target on the company's stock to €126.00, up from the previous target of €120.00. The firm...
UBS reiterated its Buy rating on shares of BioMerieux (BIM:FP) (OTC: BMXMF), with a steady price target of EUR129.00. The firm expressed increased confidence in the company following a strong first...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review